Calcium glutarate supplement and phosphorus binder
AssigneeMission Pharmacal Company
InventorsNeill B. Walsdorf SR., George Alexandrides
Life of this patent
Estimating the term…
Abstract
Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
Claims32
A method for inhibiting gastrointestinal absorption of phosphorous in a person, comprising:
- orally ingesting a quantity of calcium glutarate sufficient to bind with phosphorous in the gastrointestinal tract.
A method for inhibiting gastrointestinal absorption of phosphorous in an individual, comprising:
- orally ingesting a quantity of calcium glutarate at a mealtime.
A pharmaceutical therapeutic composition in oral dosage form for controlling phosphate retention in patients having need for reduced absorption of dietary phosphate, said composition comprising sufficient calcium glutarate to bind with phosphorus in the gastrointestinal tract, and a pharmaceutically acceptable excipient for said oral dosage form.
An orally administerable pharmaceutical composition for use in the treatment of hyperphosphatemia and for preventing the formation of phosphate- and oxalate-containing kidney stones in humans which comprises as the principal active ingredient a therapeutically effective amount of calcium glutarate combined with a pharmaceutically acceptable carrier.
A pharmaceutical compound for treating hyperphosphatemia and for preventing the formation of phosphate-containing kidney stones in humans of the formula:
- pharmaceutical grade [OOC—CH2—CH2—CH2—COO]Ca in an amount sufficient to inhibit gastrointestinal absorption of phosphorous in a person, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.